
price data provid thomson reuter
number may add due round
reiter outperform rate new target see much like current
financi report beyond initi beat manag guidanc increas
suggest confid execut commerci front persist recent
deal stealth achillion expand pipelin also broaden
potenti data catalyst phase mmpower top-lin data phase
continu explor addit therapeut indic wonder
recent patent applic suggest addit effort come
front stay consist valuat methodolog target increas
previous incorpor actual result laps partial
win take care everyth report revenu beat
non-gaap ep beat continu ultomiris/soliri convers
us pnh market coincid increas total
guidanc midpoint rang increas
ahead pre-exist consensu also notabl board director
author new share repurchas plan
pipelin execut also move along timelin larg remain track key
develop program engag regul gain feedback
potenti registr design phase studi al remain
track begin numer indic compani
plan pursu proof-of-concept also note patent applic describ
method treatment inhibitor age-rel macular degener
link check-in manag offer comment
file per polici part would seem logic extens
exist effort given literatur suggest role complement
disord moreov would appear tie effort explor
candid recent acquisit lhon ga
continu hold posit outlook think convers roadmap help
better illustr manag ultomiris/soliri strategi ampl time
complet process ahead competit entranc see remain
strong foot forward revenu estim remain larg unchang
total revenu estim high end new
guid rang increas non-gaap sg estim
reflect better tie revis guidanc note achn acquisit
anticip close thu impact stay consist
valuat methodolog target increas laps
partial discount period bottom line continu view favorit
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
alexion pharmaceut inc commercial-stag biopharmaceut compani focus develop
novel therapi rare diseas compani flagship product soliri eculizumab market
sinc approv treatment three differ therapeut indic includ paroxysm
nocturn hemoglobinuria pnh atyp hemolyt urem syndrom ahu gener myasthenia gravi
gmg beyond soliri market product portfolio encompass three addit drug recent
gain approv late call ultomiri ravulizumab-cwvz midst pipelin expans
current effort includ differ program span rang autoimmun rare diseas see
ultomiri launch enabl strong revenue/ep growth profil pipelin larg remain unmodel
stage risk/reward appear favor
major pre-exist soliri
patient convert ultomiri
pnh assum approv
ahu gmg follow
program delay fail
pipelin candid appli
progress prior biosimilar/
phase data danicopan pnh clinic
target deriv multipl
ep discount back premium vs large-
cap consensu ep due orphan
product portfolio pipelin
inc headquart
boston center excel locat new
ct flagship product soliri approv
four differ indic pnh ahu gmg nmosd
soliris/ultomiri compris major
revenu base repres primari valu driver
investor sentiment compani roll
ultomiri pnh note use limit sampl
creat bluematrix
wedbush view reiter outperform rate new target see much like
current financi report beyond initi beat manag guidanc increas suggest
confid execut commerci front persist recent deal stealth
achillion expand pipelin also broaden potenti data catalyst phase
manag acknowledg continu explor addit therapeut indic
wonder recent patent applic suggest addit effort come
front stay consist valuat methodolog target increas
previous incorpor actual result laps partial discount period
takeaway report total revenu beat consensu non-
gaap ep compani report also beat pre-exist consensu
overal complement franchis revenu beat consensu coincid
beat manag increas revenu earn guidanc rang figur
summar key result quarter differ versu consensu wedbush
guidanc updat follow report manag provid updat financi
guidanc result figur summar chang manag
updat guidanc impli total revenu midpoint
rang q/q growth manag key assumpt remain larg consist
note slight decreas price headwind vs previous overal
new revenu non-gaap ep guid rang ahead pre-exist consensu investor
like pleas direct result
pipelin updat cylind fire overal pipelin effort remain track amidst recent
deal stealth biotherapeut achillion pharmaceut focu diversif
continu end manag also initi number proof-of-concept studi
new indic ultomiri plan al studi manag process
seek regulatori guidanc across differ region remain track begin registr
studi assum typic endpoint alsfr surviv
beyond al note new patent applic us describ inhibitor
age-rel macular degener spoke compani polici
comment patent prosecut part certainli seem like logic indic
pursu complement inhibitor assum specif challeng overcom
deliveri eye achiev therapeut relev concentr although
intraven soliri previous show benefit dri wonder
potenti ultomiri set
commerci front manag provid addit granular convers dynam
across differ ultomiri indic geographi slide depict illustr
continu expans pipelin also effect increas number
potenti near-term readout shown figur numer upcom
readout next month includ full readout phase data danicopan pnh
clinic potenti top-line phase data phase result
elamipretid pmm potenti approv high-concentr ultomiris-reduc
model updat incorpor actual result make limit chang
current estim chang product revenu assumpt
total revenu estim high end guid rang pre-exist
consensu increas non-gaap sg expens assumpt
better tie updat guidanc see figur
overal remain impress execut commerci front pair
number near-term readout think pipelin begin gain traction
investor stay consist valuat methodolog appli multipl
non-gaap ep estim discount back per year
deriv target previous remain outperform rate share
incom statement ms
good sold
 expens revenu
sg expens revenu
target deriv multipl ep discount back premium vs large-cap
consensu ep due orphan product portfolio pipelin
risk attain price rate
clinic data emerg clinic studi significantli impact share either posit neg direct
regulatori alexion employ acceler strategi gain approv market product regul may requir
addit data could alter requir approv necessit addit longer studi failur gain product
label lack certain featur could limit alexion abil gain traction market
commerci failur execut commerci inabl meet/exce expect impact share
competit updat competitor may posit neg impact share relev competitor includ compani
novarti regeneron achillion competitor like emerg time
generic/biosimilar entri new gener biosimilar agent may put pressur alexion exist market product
limit compani abil realiz increas price
laura chico certifi view express report accur reflect person opinion
directli indirectli receiv compens payment connect specif recommend view contain
report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
octob
octob
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
